Celltrion Healthcare Co Ltd
KOSDAQ:091990

Watchlist Manager
Celltrion Healthcare Co Ltd Logo
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Watchlist
Price: 75 900 KRW -5.6%
Market Cap: 12.5T KRW
Have any thoughts about
Celltrion Healthcare Co Ltd?
Write Note

Gross Margin
Celltrion Healthcare Co Ltd

30%
Current
28%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
30%
=
Gross Profit
620.7B
/
Revenue
2.1T

Gross Margin Across Competitors

Country KR
Market Cap 12.2T KRW
Gross Margin
30%
Country US
Market Cap 77.7B USD
Gross Margin
4%
Country US
Market Cap 48.9B USD
Gross Margin
3%
Country US
Market Cap 48.4B USD
Gross Margin
3%
Country US
Market Cap 30.1B USD
Gross Margin
3%
Country US
Market Cap 9.3B USD
Gross Margin
32%
Country CN
Market Cap 65B CNY
Gross Margin
32%
Country CN
Market Cap 65.4B HKD
Gross Margin
8%
Country CN
Market Cap 60.9B CNY
Gross Margin
11%
Country IT
Market Cap 5.5B EUR
Gross Margin
24%
Country DE
Market Cap 5B EUR
Gross Margin
10%
No Stocks Found

Celltrion Healthcare Co Ltd
Glance View

Market Cap
12.2T KRW
Industry
Health Care

Celltrion Healthcare Co., Ltd. is a pioneering biopharmaceutical company based in South Korea, with a remarkable focus on developing and manufacturing innovative therapies that harness the power of biotechnology. Established in 2002, Celltrion has rapidly emerged as a leader in the biopharmaceutical industry, particularly known for its biosimilars and monoclonal antibody products. The company's mission is rooted in making high-quality medications more accessible and affordable on a global scale, targeting serious diseases such as cancer, autoimmune disorders, and infectious diseases. With a robust pipeline of biosimilar products aimed at offering effective alternatives to expensive biologics, Celltrion is strategically positioned to capitalize on the growing demand for cost-effective pharmaceutical solutions, especially as patent expirations of original biologics pave the way for increased competition in the market. What sets Celltrion apart is its commitment to research and development, supported by its state-of-the-art manufacturing facilities that comply with international quality standards. Its flagship products, including trastuzumab biosimilars, have already garnered approval and are being successfully marketed in multiple regions, including Europe and Asia. By leveraging cutting-edge biomanufacturing techniques and its extensive expertise, Celltrion not only reduces reliance on traditional pharmaceuticals but also addresses pressing healthcare needs globally. For investors, Celltrion presents a compelling opportunity as it continues to expand its global footprint, with increasing partnerships and collaborations aiming to unlock new markets and enhance shareholder value. As the biopharmaceutical landscape evolves, Celltrion’s innovative approach and steadfast growth trajectory position it as a formidable player, making it a company worth watching for anyone interested in the future of healthcare.

Intrinsic Value
64 150.76 KRW
Overvaluation 15%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
30%
=
Gross Profit
620.7B
/
Revenue
2.1T
What is the Gross Margin of Celltrion Healthcare Co Ltd?

Based on Celltrion Healthcare Co Ltd's most recent financial statements, the company has Gross Margin of 30%.